Immunomedics

IMMU NASDAQ
13.16
-0.46
-3.38%
After Hours: 13.18 +0.02 +0.15% 19:46 08/23 EDT
Open
13.60
Prev Close
13.62
High
13.76
Low
13.08
Volume
2.13M
Avg Vol (3M)
2.26M
52 Week High
26.99
52 Week Low
11.55
% Turnover
1.11%
Market Cap
2.53B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Immunomedics IMMU stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.
MORE >

Recently

Name
Price
%Change